This article is more than 5 years old. Information may no longer be current.
Topcon receives FDA approval for new digital fundus camera
Click Here to Manage Email Alerts
PARAMUS, N.J. — Topcon Medical Systems has received clearance from the U.S. Food and Drug Administration for its new TRC-NW7SF Mark II digital fundus camera, the company announced in a press release.
The new model employs mydriatic and non-mydriatic functions to perform documentation procedures, including intravenous fluorescein angiography and non-mydriatic full-color retinal screening. Images are viewable in color and monochromatic modes with minimal image capture delay, according to the release.
In addition, the camera is equipped to interface with Topcon's EyeRoute system to view, compare, organize, annotate and share imaging management information.
"Until now, most retinal cameras have been specifically manufactured to be operated by a highly trained photographer," Lon Dowell, Topcon's director of marketing for imaging products, said in the release. "But now we can bridge the gap in staff training to provide for the needs of a growing patient population and give the comprehensive ophthalmologist a better tool to help diagnose and treat many sight-threatening illnesses."
Topcon plans to begin marketing the camera immediately, with a formal launch slated for the American Academy of Ophthalmology meeting in San Francisco.